Lupin Settles Patent Dispute With U.S. Makers Of Glumetza Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Lupin Pharmaceuticals agreed to a patent-settlement with two U.S.-based companies, Santarus and Depomed, giving Lupin a chance at an early launch of a generic of the diabetes drug, Glumetza (metformin).